Barclays PLC Purchases 18,761 Shares of XBiotech Inc. (NASDAQ:XBIT)

Barclays PLC increased its position in shares of XBiotech Inc. (NASDAQ:XBIT) by 247.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,343 shares of the biopharmaceutical company’s stock after purchasing an additional 18,761 shares during the period. Barclays PLC’s holdings in XBiotech were worth $204,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Jane Street Group LLC bought a new stake in shares of XBiotech during the 3rd quarter valued at $86,000. MetLife Investment Management LLC purchased a new position in XBiotech during the third quarter valued at $94,000. Rhumbline Advisers grew its stake in XBiotech by 2,568.5% during the second quarter. Rhumbline Advisers now owns 20,094 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 19,341 shares in the last quarter. FMR LLC grew its stake in XBiotech by 34.4% during the third quarter. FMR LLC now owns 28,992 shares of the biopharmaceutical company’s stock valued at $224,000 after acquiring an additional 7,420 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in XBiotech by 184.9% during the third quarter. BNP Paribas Financial Markets now owns 40,040 shares of the biopharmaceutical company’s stock valued at $310,000 after acquiring an additional 25,987 shares in the last quarter. 55.70% of the stock is currently owned by institutional investors.

XBiotech Stock Performance

XBIT opened at $3.83 on Wednesday. The stock has a market capitalization of $116.74 million, a price-to-earnings ratio of -3.55 and a beta of 1.44. The company has a fifty day moving average of $5.65 and a 200 day moving average of $6.44. XBiotech Inc. has a fifty-two week low of $3.51 and a fifty-two week high of $9.96.

About XBiotech

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.